Caren L. Freel-Meyers

Image of Dr. Caren Meyers

Caren L. Freel-Meyers

Associate Professor
Primary Appointment: 
Pharmacology and Molecular Sciences
410-502-4808

725 N. Wolfe Street
WBSB 307B
Baltimore MD 21205

Research topic: 

Medicinal chemistry, chemical biology, drug delivery, bacterial isoprenoid and vitamin and biosynthesis, design of anti-infective strategies

We take chemical-biology approaches to pursue new anti-infective strategies. Since 2005, my group has developed approaches to block the indispensable MEP pathway for isoprenoid biosynthesis and vitamin biosynthesis in pathogens. DXP synthase has emerged from this work as a particularly promising target in bacterial metabolism that we are rigorously investigating. We have pioneered studies to understand the mechanism underlying the unique activity of DXP synthase, and developed the first selective probes of DXP synthase that are currently enabling key advances toward the understanding this target function in the context of infection, and toward in vivo target validation. Our work on anti-infective drug targets is complemented by our research focused on developing prodrug strategies to treat and prevent infectious disease, including bacterial infection and HIV. Projects in this area focus on strategies to overcome barriers of low cell permeability of clinical agents, or chemical probes we develop to study antibacterial targets, including DXP synthase. We are also developing drug delivery strategies for the NRTI antiretroviral class, toward development of injectable or implantable sustained release antiretroviral drug regimens.

BCMB students currently in the lab:
Selected Publications: 

Bartee D, Freel Meyers CL. Targeting the Unique Mechanism of Bacterial 1-Deoxy-D-xylulose-5-phosphate Synthase. Biochemistry 2018, 57, 4349-4356. PubMed Central PMCID: PMC6057799.

DeColli AA, Nemeria NS, Majumdar A, Gerfen GJ, Jordan F, Freel Meyers CL. Oxidative decarboxylation of pyruvate by 1-deoxy-D-xyulose 5-phosphate synthase, a central metabolic enzyme in bacteria. J. Biol. Chem. 2018, 293, 10857-10869. PubMed Central PMCID: PMC6052232.

Sanders S, Vierling RJ, Bartee D, DeColli AA, Harrison MJ, Aklinski JL, Koppisch AT, Freel Meyers CL. Challenges and Hallmarks of Establishing Alkylacetylphosphonates as Probes of Bacterial 1-Deoxy-D-xylulose 5-Phosphate Synthase. ACS Infect Dis. 2017, 3, 467-478. PubMed Central PMCID: PMC5650741.

DeColli AA, Zhang X, Heflin KL, Jordan F, Freel Meyers CL. Active Site Histidines Link Conformational Dynamics with Catalysis on Anti-Infective Target 1-Deoxy-D-xylulose 5-Phosphate Synthase. Biochemistry 2019, 58, 4970-4982. PubMed Central PMCID: PMC6905430.

Hobson JJ, Al-Khouja A, Curley P, Meyers D, Flexner C, Siccardi M, Owen A, Meyers CF, Rannard SP. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nat Commun. 2019, 10, 1413. PubMed Central PMCID: PMC6441007.

Bartee D, Sanders S, Phillips PD, Harrison MJ, Koppisch AT, Freel Meyers CL. Enamide Prodrugs of Acetyl Phosphonate Deoxy-D-xylulose-5-phosphate Synthase Inhibitors as Potent Antibacterial Agents. ACS Infect Dis. 2019, 5, 406-417. PubMed PMID: 30614674.

Armstrong CM, Meyers DJ, Imlay LS, Freel Meyers C, Odom AR. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr). Antimicrob Agents Chemother. 2015, 59, 5511-9. PubMed Central PMCID: PMC4538460.

Webster MR, Zhao M, Rudek MA, Hann CL, Freel Meyers CL. Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. J. Med. Chem. 2011, 54, 6647-56. PubMed Central PMCID: PMC3188694.